Buy Stocks Easy | About Us

September 17, 2021

BCRX

Buy BioCryst Pharmaceuticals, Inc. Stock (symbol: BCRX) Easy Online

Company Name: BioCryst Pharmaceuticals, Inc.

Symbol: BCRX

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

IPO:

BCRX Current Share Price

Today's BCRX ( BioCryst Pharmaceuticals, Inc. ) opening price: $3.2100

Yesterday's BCRX ( BioCryst Pharmaceuticals, Inc. ) closing price: $3.2000

BioCryst Pharmaceuticals, Inc. Stock ( symbol: BCRX ) Price Chart since IPO ():

12 Months BioCryst Pharmaceuticals, Inc. Stock ( symbol: BCRX ) Price Chart

Popular Questions about BioCryst Pharmaceuticals, Inc. Public Stock ( BCRX )

A: BioCryst Pharmaceuticals, Inc. stock symbol (also called stock or share ticker) is BCRX

A: BioCryst Pharmaceuticals, Inc. IPO (Initial Public Offering) took place on

A: BioCryst Pharmaceuticals, Inc.'s stock (BCRX symbol) price at ther IPO (initial Public Offering) was $3.2100

Q: Is BCRX stock worth buying at the moment?

A: The BCRX stock performance since 2019 are rather disappointing. If you had bought 1 share of BioCryst Pharmaceuticals, Inc. stock (symbol: BCRX) at the beginning of 2019, at the opening share price of $, you would be left with exactly $3.2100 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy BioCryst Pharmaceuticals, Inc. Stock Easy Online

BioCryst Pharmaceuticals, Inc. Stock Ticker Price Chart since IPO:

BioCryst Pharmaceuticals, Inc. Stock Price Yesterday

BioCryst Pharmaceuticals, Inc. Stock Price – Last Week

BioCryst Pharmaceuticals, Inc. Stock Price – Last Month

BioCryst Pharmaceuticals, Inc. Stock Value Chart – 12 Months

Rate this post

Latest Stock News:

http://www.zacks.com/stock/news/667692/biocryst-submits-nda-for-hereditary-angioedema-candidate

BioCryst Submits NDA for Hereditary Angioedema Candidate

BioCryst (BCRX) files a new drug application to the FDA for once-da...

http://www.globenewswire.com/news-release/2019/12/11/1959132/0/en/BioCryst-Submits-New-Drug-Application-for-Oral-Once-Daily-Berotralstat-BCX7353-to-Prevent-HAE-Attacks.html

BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2019 (GLOBE NEWSWIRE) -- B...

http://www.zacks.com/stock/news/654156/implied-volatility-surging-for-biocryst-bcrx-stock-options

Implied Volatility Surging for BioCryst (BCRX) Stock Options

Investors need to pay close attention to BioCryst (BCRX) stock base...

http://www.globenewswire.com/news-release/2019/12/04/1956061/0/en/BioCryst-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2019 (GLOBE NEWSWIRE) -- B...

https://seekingalpha.com/article/4308638-biocryst-stock-price-turning-point

BioCryst: The Stock Price Is At A Turning Point

BioCryst: The Stock Price Is At A Turning Point

http://www.globenewswire.com/news-release/2019/11/18/1948965/0/en/BioCryst-Announces-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares-and-Completion-of-Public-Offering-of-Common-Stock.html

BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2019 (GLOBE NEWSWIRE) -- B...

https://www.benzinga.com/analyst-ratings/analyst-color/19/11/14820964/bank-of-america-upgrades-biocryst-as-financing-overhang-lifts-partially

Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) completed a $55 milli...

http://www.globenewswire.com/news-release/2019/11/14/1946804/0/en/BioCryst-Prices-Public-Offering-of-Common-Stock.html

BioCryst Prices Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- B...

https://seekingalpha.com/article/4304473-biocryst-new-actor-alternative-pathway-inhibition-field

BioCryst: A New Actor In The Alternative Pathway Inhibition Field

BioCryst: A New Actor In The Alternative Pathway Inhibition Field

https://seekingalpha.com/article/4303361-biocryst-pharmaceuticals-inc-bcrx-ceo-jon-stonehouse-q3-2019-results-earnings-call-transcript

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2019 Results - Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2019...

All right reserved Buy Stocks Easy , 2019.